Cadrenal Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 03/31/08 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Cost of revenue | — | — | $220,095 | — | $220,095 |
| Research and development | $4.1M | $4.2M | $4.1M | $392,859 | $200,000 |
| Operating expenses | $13.5M | $11.0M | $7.6M | $2.7M | — |
| Operating income | -$13.5M | -$11.0M | -$7.6M | -$2.7M | — |
| Interest expense | — | — | $3,534 | $40,192 | — |
| Net income | -$13.2M | -$10.7M | -$8.4M | -$6.7M | — |
| Balance Sheet | |||||
| Cash and equivalents | $4.0M | $10.0M | $8.4M | $32,586 | — |
| Current assets | $4.3M | $10.1M | $8.5M | $727,596 | — |
| Total assets | $4.3M | $10.1M | $8.5M | $778,174 | — |
| Current liabilities | $1.6M | $2.7M | $826,875 | $1.3M | — |
| Total liabilities | $1.6M | $2.7M | $826,875 | $6.3M | — |
| Stockholders' equity | $2.7M | $7.4M | $7.7M | -$5.6M | — |
| Cash Flow Statement | |||||
| Cash from operations | -$12.6M | -$7.4M | -$3.5M | -$1.2M | — |
| Depreciation and amortization | $6,874 | $1,880 | $1,980 | $1,266 | — |
| Stock-based compensation | $1.9M | $1.4M | $710,381 | $928,049 | — |
| Capital expenditure | $5,104 | $6,537 | $3,254 | $2,279 | — |
| Free cash flow | -$12.6M | -$7.4M | -$3.5M | -$1.2M | — |
Shares outstanding 2.9M · Free float 82.6%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.